- Home
- DOMO vs ZNTL Comparison
DOMO vs ZNTL Comparison
Compare DOMO & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOMO | ZNTL |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.3M | 195.8M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DOMO | ZNTL |
|---|---|---|
| Price | $2.51 | $6.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $11.15 | $5.80 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 05-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $317,044,000.00 | N/A |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $4.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.56 | $1.13 |
| 52 Week High | $18.49 | $4.50 |
Technical Indicators
Market Signals| Indicator | DOMO | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 27.27 | 86.41 |
| Support Level | N/A | $1.31 |
| Resistance Level | $5.39 | N/A |
| Average True Range (ATR) | 0.23 | 0.45 |
| MACD | -0.02 | 0.31 |
| Stochastic Oscillator | 0.75 | 91.80 |
Price Performance
Historical ComparisonAbout DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.